Logo

Asuragen Lab Gains CAP Accreditation

Dec 17, 2009

NEW YORK (GenomeWeb News) – Diagnostics developer Asuragen said today that is has received accreditation as a CLIA-compliant lab by the College of American Pathologists (CAP).

The Austin, Texas-based firm said that the CAP accreditation is "a crucial step" in its plans to begin commercializing its miRNA-based oncology and clinical sample testing services.

"This is a significant step forward in our efforts to bring novel molecular diagnostic tests for oncology to market, and to offer our pharmaceutical clients a means to develop and validate companion diagnostic tests," Asuragen CEO Matt Winkler said in a statement.

The company currently is preparing its miRNA Pancreatic FFPE Test for diagnosing pancreatic adenocarcinoma.

Filed under

Diagnostics
Gene Editing, Gene Silencing, & CRISPR
Molecular Diagnostics
Regulatory News & FDA Approvals
accreditation
CAP
RNAi
Asuragen
Breaking News
The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.